Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis

Eur J Nucl Med Mol Imaging. 2006 May;33(5):553-6. doi: 10.1007/s00259-005-0049-3. Epub 2006 Mar 8.

Abstract

In the framework of the preclinical validation of the hypoxic tracer [(18)F]EF3, a comparison was performed between uptake of [(18)F]EF3 and EF5 adducts detected by immunofluorescence in MCa-4, FSA, FSAII, Sa-NH and NFSA tumour-bearing mice. Mice were allowed to breath carbogen (5% CO(2), 95% O(2)), 21% oxygen or 10% oxygen. A significant correlation (r (2)=0.57; p<0.01) was found between the [(18)F]EF3 tumour-to-muscle ratio and the fluorescence intensity of EF5.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Hypoxia
  • Drug Evaluation, Preclinical
  • Etanidazole / analogs & derivatives*
  • Etanidazole / metabolism
  • Fibrosarcoma / diagnostic imaging*
  • Fibrosarcoma / metabolism*
  • Fluorescent Antibody Technique
  • Hydrocarbons, Fluorinated / metabolism*
  • Male
  • Mammary Neoplasms, Experimental / diagnostic imaging*
  • Mammary Neoplasms, Experimental / metabolism*
  • Metabolic Clearance Rate
  • Mice
  • Mice, Inbred C3H
  • Nitroimidazoles / pharmacokinetics*
  • Organ Specificity
  • Oxygen / metabolism*
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics
  • Tissue Distribution

Substances

  • 2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide
  • Hydrocarbons, Fluorinated
  • Nitroimidazoles
  • Radiopharmaceuticals
  • Etanidazole
  • 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide
  • Oxygen